Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of  patients with elevated LDL-C.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 2:13 PM ET on Oct 27, 2016
Last Price Change Open Day High 52-Week High
0.44  down   (3.764%) 11.81 11.98 30.41
Volume Previous Close Day Low 52-Week Low
124,734 11.69 11.22 9.58

View all »   RSSRecent Releases

Oct 13, 2016
Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose

Aug 4, 2016
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results